1. Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: clinical and genetic aspects. Orphanet J Rare Dis. 2011; 6(80): 1750-1172. DOI: 10.1186/1750-1172-6-80.
2. Kaplan FS, Le Merrer M, Glaser DL, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol. 2008; 22(1): 191-205. https://doi.org/10.1016/j.berh.2007.11.007.
3. Kaplan FS, Meiqi Xu, Petra Seemann, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat. 2009; 30(3): 379-390. https://doi.org/10.1002/humu.20868.
4. Solomon D, Wakjira I, Hailu D, et al. Fibroplasia Ossificans Progressiva: A Case Report of a Rare Disease Entity. Ethiop J Health Sci. 2018; 28(4):513-516. DOI: 10.4314/ejhs.v28i4.17.
5. Kitterman JA, Kantanie S, Rocke DM, et al. Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics. 2005; 116(5): e654-661. DOI: 10.1542/peds.2005-0469.
6. Kaplan FS, Pignolo RJ, Shore EM. The FOP metamorphogene encodes a novel type I receptor that dysregulates BMP signaling. Cytokine Growth Factor Rev. 2009; 20(5-6): 399-407. https://doi.org/10.1016/j.cytogfr.2009.10.006.
7. Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006; 38(5): 525-527. DOI: 10.1038/ng1783.
8. Wentworth KL, Masharani U, Hsiao EC. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva. Br J Clin Pharmacol 2019 Jun;85(6). https://doi.org/10.1111/bcp.13823.
9. Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons. Pediatr Endocrinol Rev. 2013: 10(2): 437-448.
10. Kaplan FS, Zasloff MA, Kitterman JA, et al. Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am. 2010; 92(3): 686-691. DOI: 10.2106/JBJS.I.00705.
11. Wei Zhang, Keqin Zhang, Lige Song, et al. The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases. Bone. 2013; 57(2): 386-391. https://doi.org/10.1016/j.bone.2013.09.002.
12. She D, Zhang K. Fibrodysplasia ossificans progressiva in China. Bone. 2018; 109:101-103. https://doi.org/10.1016/j.bone.2017.11.016.
13. Jiao S, Zhang Y, Ma W, et al. FOP in China and Japan: an overview from domestic literatures. Am J Med Genet A. 2013; 161A (4): 892-893. https://doi.org/10.1002/ajmg.a.35771.
14. Morales-Piga A, Bachiller-Corral J, Trujillo-Tiebas MJ, et al. Fibrodysplasia ossificans progressiva in Spain: epidemiological, clinical, and genetic aspects. Bone. 2012; 51(4): 748-755. https://doi.org/10.1016/j.bone.2012.07.002.
15. Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int. 2009; 20(6): 843-851. DOI: 10.1007/s00198-009-0838-9.
16 Bayer M. Reference values of osteocalcin and procollagen type I N-propeptide plasma levels in a healthy Central European population aged 0-18 years. Osteoporos Int. 2014 Feb;25(2):729-36. DOI: 10.1007/s00198-013-2485-4.
17. Yuqi Luo, Xiaojing Ma, Yaping Hao, et al. Relationship between serum osteocalcin level and carotid intima-media thickness in a metabolically healthy Chinese population. Cardiovasc Diabetol. 2015; 14: 82. DOI: 10.1186/s12933-015-0245-9.
18. Fiori JL, Billings PC, de la Peña LS, et al. Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res. 2006, 21(6):902-909. https://doi.org/10.1359/jbmr.060215.
19. Zhang X, Shen Y, Xu Y, et al. Association of serum osteocalcin levels with major adverse cardiovascular events: A 4.4-year retrospective cohort study. Clin Exp Pharmacol Physiol. 2018; 45: 3–9. https://doi.org/10.1111/1440-1681.12853.
20. Yeap BB, Chubb SA, Flicker L, et al. Associations of total osteocalcin with all-cause and cardiovascular mortality in older men. The Health In Men Study. Osteoporos Int. 2012; 23(2): 599-606. DOI: 10.1007/s00198-011-1586-1.